Contributions
Abstract: 67
Type: Educational Session
Abstract Category: N/A
Control of progression in progressive multiple sclerosis (MS) naturally remains a major goal, although ultimately repair and remyelination will be needed. Robust controlled and randomised trials remain the bedrock by which an intervention is judged. In the last five years many phase 2 trials have reported in this area, with four large phase 3 trials since 2016. The question arises whether this fundamental work can be done quicker and more efficiently. This presentation will look at current views over the range of adaptive concepts and how they could be applied to future progressive MS trials.
Disclosure: The author has received support from the Efficacy and Mechanism Evaluation Programme and Health Technology Assessment Programme (NIHR); UK Multiple Sclerosis Society and National Multiple Sclerosis Society. In the last 3 years, he has been a local principal investigator for trials in multiple sclerosis funded by Receptos, Novartis, and Biogen Idec, and has received an investigator grant from Novartis outside this work. He has taken part in advisory boards/consultancy for Roche, Merck KGaA Germany, MedDay,Biogen, and Apitope.
Abstract: 67
Type: Educational Session
Abstract Category: N/A
Control of progression in progressive multiple sclerosis (MS) naturally remains a major goal, although ultimately repair and remyelination will be needed. Robust controlled and randomised trials remain the bedrock by which an intervention is judged. In the last five years many phase 2 trials have reported in this area, with four large phase 3 trials since 2016. The question arises whether this fundamental work can be done quicker and more efficiently. This presentation will look at current views over the range of adaptive concepts and how they could be applied to future progressive MS trials.
Disclosure: The author has received support from the Efficacy and Mechanism Evaluation Programme and Health Technology Assessment Programme (NIHR); UK Multiple Sclerosis Society and National Multiple Sclerosis Society. In the last 3 years, he has been a local principal investigator for trials in multiple sclerosis funded by Receptos, Novartis, and Biogen Idec, and has received an investigator grant from Novartis outside this work. He has taken part in advisory boards/consultancy for Roche, Merck KGaA Germany, MedDay,Biogen, and Apitope.